Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142831 · ClinicalTrials.gov registry record · Phase 4
Bupropion as an Adjunct to the Nicotine Patch Plus CBT
A Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 293
- Enrollment target
NCT00142831 is a Phase 4 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 293 participants.
The verdict
NCT00142831, a Phase 4 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 293 participants
- Enrollment target
Study Summary
Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.
Interventions
- DRUG Pharmacotherapies for Smoking Cessation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 1999-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142831
The ClinicalTrials.gov registry entry for NCT00142831 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacotherapies for Smoking Cessation is the first listed.
NCT00142831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142831 about?
NCT00142831 is a clinical study titled "Bupropion as an Adjunct to the Nicotine Patch Plus CBT". Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to d...
What is the current status of trial NCT00142831?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 293 participants. The study started on 1999-04. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00142831?
The interventions under investigation include: Pharmacotherapies for Smoking Cessation (DRUG).
Who is sponsoring clinical trial NCT00142831?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.